Studies utilising both a mouse model of obesity-induced T2DM (db/db) and rat mesangial cells treated with high (30 mM) glucose, reported that podocyte injury, basement membrane thickness, foot process effacement and fibrosis, were all decreased when mice and cells were treated with MCC950, a small molecule inhibitor that blocks NLRP3 activation (Zhang et al., 2019). This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.